卡维迪洛尔在患有无法控制和抗性高血压的患者中
Z Kereselidze1, L Kopaleishvili2, K Nadaraia3
11Department of ICCU, Tbilisi Heart Center, Georgia.
Georgian medical news
|December 26, 2024
概括
卡维迪醇在耐性高血压患者 (包括不耐受通道阻塞剂的患者) 中有效降低了静缩和静缩血压. 这种具有α-1阻断功能的非选择性β抑制剂提供了一种安全和有益的治疗选择.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 高血压管理 高血压管理
背景情况:
- 耐性高血压的管理需要进一步调查β-阻断剂的疗效.
- 之前的研究,如PATHWAY-2,显示了比索醇的益处,但没有完全解决腹压血压或通道阻断剂 (CCB) 不耐受.
- 了解不同β抑制剂的作用对于指导复杂高血压患者的治疗至关重要.
研究的目的:
- 为了评估卡维迪醇的疗效,一个非选择性的β-阻断剂与α-1阻断性质,在治疗耐药高血压.
- 评估卡维迪洛在不能容忍通道阻断剂 (CCBs) 的患者中的有效性.
- 为了比较carvedilol在以前未接受治疗的患者中启动时的疗效,与从另一种β-阻断剂转换时的疗效.
主要方法:
- 研究了两个组:"添加卡维迪洛尔" (曾经接受过β阻断剂的高血压耐药患者在三重治疗中) 和"切换到卡维迪洛尔" (从比索普罗洛尔切换到卡维迪洛尔的CCB不耐受患者).
- 主要终点:从基线开始,缩血压 (SBP) 和腹缩血压 (DBP) 的变化.
- 二级终点:血压降低与人口统计和安全参数 (低血压,心肌梗塞,新发型2型糖尿病) 的相关性.
主要成果:
- 在"添加卡维迪醇"和"切换到卡维迪醇"组中观察到SBP和DBP的显著降低.
- 卡维迪洛尔在接受标准三重治疗 (CCB,RAAS抑制剂,利尿剂) 的患者和对CCB不耐受患者中表现出有效性.
- 药物耐受性良好,没有报告任何重大不良事件,这表明药物的安全性状况良好.
结论:
- 卡维迪醇是耐药高血压患者的有效治疗选择.
- 该研究支持使用卡维迪醇,特别是在不能耐受通道阻塞剂的患者中.
- 卡维迪醇可显著降低血压,在耐性高血压管理中具有良好的耐受性.
更多相关视频
08:35Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.0K
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
1.3K
相关概念视频
01:22Heart Failure Drugs: β-Blockers
259
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
259
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
378
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
378
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
302
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
384
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
384
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
529
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
529
01:23Antihypertensive Drugs: Vasodilators
426
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
426